MSD has been rocked by a court judgment ordering it to stop manufacturing and selling its subcutaneous formulation of cancer ...

Novartis' oral BTK inhibitor Rhapsido has had its label expanded in the US to include ​a second indication, symptomatic ...

Klick Health's recent acquisition of Oxford PharmaGenesis reflects that shift. “Clearly for a lot of reasons that have been ...

A survey of senior figures in European biopharma companies has found that dealmaking and M&A are expected to increase, with ...

Novartis has a much-anticipated approval for its spinal muscular atrophy (SMA) treatment onasemnogene abeparvovec in the US, getting a green light for a new version that can make more patients ...

Wegovy has since been joined in the UK market by Eli Lilly's oral GLP-1 agonist Foundayo (orforglipron), which was approved by the MHRA in August. Neither product is covered by the NHS, but can be ...

Day One Strategy’s second annual AI in Pharma State of Play report – Are Insights leaders seeing real commercial value from AI adoption yet? – addresses the challenges Pharma Insights teams are facing ...

The governor of New York has said that rising cases of measles constitute a "statewide disaster emergency," the first such ...

Click Therapeutics has won the first-ever FDA approval for a treatment for the negative symptoms of schizophrenia – a digital ...

As antibody-drug conjugates (ADCs) continue to establish themselves as a cornerstone of modern oncology, breakthrough ...

This is not simply a broader role for Market Access. It is an emerging leadership capability for the healthcare business.

AstraZeneca's pivot towards the US market has continued with the opening of a new R&D centre in the biotech hotspot of ...